Table 1.
Patient characteristics.
| BOLOGNA (Italy) |
PREDICROHN (Spain) |
STRIDENT (Australia) |
PRECISION (USA) |
All cohorts |
|
|---|---|---|---|---|---|
| Anti-TNFs | ADA | ADA/IFX | ADA | IFX | ADA/IFX |
| Crohn’s disease | 100% (53/53) | 100% (112/112) | 100% (77/77) | 73% (125/173) | 88%% (367/415) |
| Prior biologics | 30% (16/53) | 0% (0/112) | 12% (9/77) | 22% (38/173) | 15% (63/415) |
| Age (years) | 24 (26; 44) | 39 (29; 50) | 44 (30; 52) | 15 (12; 17) | 27 (15; 43) |
| Gender (female) | 36% (19/53) | 48% (54/112) | 51% (39/77) | 46% (79/173) | 46% (191/415) |
| Weight at baseline | 67 (60; 78) | 64 (57; 76) | 78 (66; 87) | 45 (33; 59) | 61 (46; 73) |
| ALB at baseline | 3.9 (3.8; 4.2) | 3.8 (3.3; 4.4) | 3.7 (3.5; 3.9) | 3.2 (2.8; 3.7) | 3.6 (3.0; 4.0) |
| HLA DQA1*05 carriage | 47% (25/53) | 37% (42/112) | 27% (21/77) | 46% (80/173) | 40% (168/415) |
| CL > 0.326 L/day | 51% (27/53) | 49% (55/112) | 79% (61/77) | 42% (72/173) | 52% (215/415) |
| Responder score >0 | 79% (42/53) | 67% (75/112) | 86% (66/77) | 69% (120/173) | 73% (303/415) |
| Responder score >1 | 19% (10/53) | 20% (22/112) | 21% (16/77) | 18% (32/173) | 19% (80/415) |
| Antibodies (anytime) | 23% (12/53) | 16% (18/112) | 14% (11/77) | 13% (23/173) | 15% (64/415) |
| Antibodies all cycles | 15% (28/182) | 11% (70/614) | 8% (24/285) | 4% (34/930) | 8% (156/2011) |
| CRP-based clinical rem. | 47% (28/182) | 44% (235/535) | 45% (113/250) | 52% (487/930) | 49% (919/1893) |
| SES-CD | 1 (0; 4) | NA | 3 (0; 8) | NA | 3 (0; 6) |
| SES-CD ≥ 3 | 43% (39/90) | NA | 64% (35/55) | NA | 51% (74/145) |
| Maintenance cycles | 3.4 (182) | 4.5 (507) | 2.7 (208) | 2.5 (434) | 3.2 (1331) |
| Trough concentrations | 10 (5.2; 12.8) | 8.0 (3.9; 12.2) | 13.2 (8.2; 18.0) | 12.3 (8.3; 18.0) | 10.2 (6.0; 15.1) |
Results are expressed as median IQR or % (n/N), as appropriate.
SES-CD, Simple Endoscopic Score for Crohn’s Disease.
NA, not available.